» Articles » PMID: 32083977

Pathogenic Mechanisms and the Potential of Drug Therapies for Aortic Aneurysm

Overview
Authors
Affiliations
Soon will be listed here.
Abstract

Aortic aneurysm is a permanent focal dilation of the aorta. It is usually an asymptomatic disease but can lead to sudden death due to aortic rupture. Aortic aneurysm-related mortalities are estimated at ∼200,000 deaths per year worldwide. Because no pharmacological treatment has been found to be effective so far, surgical repair remains the only treatment for aortic aneurysm. Aortic aneurysm results from changes in the aortic wall structure due to loss of smooth muscle cells and degradation of the extracellular matrix and can form in different regions of the aorta. Research over the past decade has identified novel contributors to aneurysm formation and progression. The present review provides an overview of cellular and noncellular factors as well as enzymes that process extracellular matrix and regulate cellular functions (e.g., matrix metalloproteinases, granzymes, and cathepsins) in the context of aneurysm pathogenesis. An update of clinical trials focusing on therapeutic strategies to slow abdominal aortic aneurysm growth and efforts underway to develop effective pharmacological treatments is also provided.

Citing Articles

Cross-sectional study of lung cancer patients as a potential high-risk factor for abdominal aortic aneurysm.

Gwon H, Woo A, Yong S, Park Y, Kim S, Kim E PLoS One. 2025; 20(1):e0315898.

PMID: 39761267 PMC: 11703101. DOI: 10.1371/journal.pone.0315898.


HMGCR as a promising molecular target for therapeutic intervention in aortic aneurisms: a mendelian randomization study.

Zheng P, Zheng Z, Liu Z, He J, Rong J, Pan H Nutr Metab (Lond). 2024; 21(1):81.

PMID: 39402528 PMC: 11472594. DOI: 10.1186/s12986-024-00849-1.


Prevalence and Influence of Genetic Variants on Follow-Up Results in Patients Surviving Thoracic Aortic Therapy.

Ghazy T, Elzanaty N, Lackner H, Irqsusi M, Rastan A, Behrendt C J Clin Med. 2024; 13(17).

PMID: 39274466 PMC: 11396620. DOI: 10.3390/jcm13175254.


Exploiting the anti-fibrotic effects of statins on thoracic aortic aneurysm progression: results from a meta-analysis and experimental data.

Myasoedova V, Rega S, Valerio V, Moschetta D, Massaiu I, Bonalumi G Front Pharmacol. 2024; 15:1426982.

PMID: 39148550 PMC: 11324425. DOI: 10.3389/fphar.2024.1426982.


Vascular Endothelial Growth Factor Inhibitors and the Risk of Aortic Aneurysm and Aortic Dissection.

Wu C, Huang H, Lin S, Wang C, Huang C, Wu I JAMA Netw Open. 2024; 7(3):e240940.

PMID: 38436956 PMC: 10912963. DOI: 10.1001/jamanetworkopen.2024.0940.


References
1.
Hamada H, Garcia-Hernandez M, Reome J, Misra S, Strutt T, McKinstry K . Tc17, a unique subset of CD8 T cells that can protect against lethal influenza challenge. J Immunol. 2009; 182(6):3469-81. PMC: 2667713. DOI: 10.4049/jimmunol.0801814. View

2.
Takahashi N, Duprez L, Grootjans S, Cauwels A, Nerinckx W, DuHadaway J . Necrostatin-1 analogues: critical issues on the specificity, activity and in vivo use in experimental disease models. Cell Death Dis. 2012; 3:e437. PMC: 3542611. DOI: 10.1038/cddis.2012.176. View

3.
Longo G, Buda S, Fiotta N, Xiong W, Griener T, Shapiro S . MMP-12 has a role in abdominal aortic aneurysms in mice. Surgery. 2005; 137(4):457-62. DOI: 10.1016/j.surg.2004.12.004. View

4.
Holmes D, Lopez-Candales A, Liao S, Thompson R . Smooth muscle cell apoptosis and p53 expression in human abdominal aortic aneurysms. Ann N Y Acad Sci. 1996; 800:286-7. DOI: 10.1111/j.1749-6632.1996.tb33334.x. View

5.
Polykratis A, Hermance N, Zelic M, Roderick J, Kim C, Van T . Cutting edge: RIPK1 Kinase inactive mice are viable and protected from TNF-induced necroptosis in vivo. J Immunol. 2014; 193(4):1539-1543. PMC: 4119562. DOI: 10.4049/jimmunol.1400590. View